{"id":2123,"date":"2025-09-30T11:01:22","date_gmt":"2025-09-30T04:01:22","guid":{"rendered":"https:\/\/biomedmart.com.vn\/?p=2123"},"modified":"2025-09-30T11:01:53","modified_gmt":"2025-09-30T04:01:53","slug":"car-t-lieu-phap-te-bao-t-thu-the-khang-nguyen-kham","status":"publish","type":"post","link":"https:\/\/biomedmart.com.vn\/etc\/2025\/09\/30\/car-t-lieu-phap-te-bao-t-thu-the-khang-nguyen-kham\/","title":{"rendered":"CAR-T: Li\u1ec7u ph\u00e1p\u00a0t\u1ebf b\u00e0o T th\u1ee5 th\u1ec3 kh\u00e1ng nguy\u00ean kh\u1ea3m"},"content":{"rendered":"\n

Li\u1ec7u ph\u00e1p t\u1ebf b\u00e0o th\u1ee5 th\u1ec3 kh\u00e1ng nguy\u00ean kh\u1ea3m tr\u00ean t\u1ebf b\u00e0o T (Chimeric Antigen Receptor T-cell – CAR-T) l\u00e0 m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb mi\u1ec5n d\u1ecbch mang t\u00ednh c\u00e1ch m\u1ea1ng, thu\u1ed9c nh\u00f3m li\u1ec7u ph\u00e1p chuy\u1ec3n t\u1ebf b\u00e0o nu\u00f4i, trong \u0111\u00f3 c\u00e1c t\u1ebf b\u00e0o lympho T c\u1ee7a ch\u00ednh b\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c bi\u1ebfn \u0111\u1ed5i di truy\u1ec1n \u0111\u1ec3 bi\u1ec3u hi\u1ec7n m\u1ed9t th\u1ee5 th\u1ec3 t\u1ed5ng h\u1ee3p. Th\u1ee5 th\u1ec3 n\u00e0y, \u0111\u01b0\u1ee3c g\u1ecdi l\u00e0 CAR, cho ph\u00e9p c\u00e1c t\u1ebf b\u00e0o T \u0111\u00e3 \u0111\u01b0\u1ee3c t\u00e1i l\u1eadp tr\u00ecnh c\u00f3 kh\u1ea3 n\u0103ng nh\u1eadn di\u1ec7n v\u00e0 ti\u00eau di\u1ec7t c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 m\u1ed9t c\u00e1ch \u0111\u1eb7c hi\u1ec7u. Do kh\u1ea3 n\u0103ng t\u1ed3n t\u1ea1i, nh\u00e2n l\u00ean v\u00e0 th\u1ef1c hi\u1ec7n ch\u1ee9c n\u0103ng gi\u00e1m s\u00e1t mi\u1ec5n d\u1ecbch l\u00e2u d\u00e0i trong c\u01a1 th\u1ec3 b\u1ec7nh nh\u00e2n, c\u00e1c t\u1ebf b\u00e0o CAR-T th\u01b0\u1eddng \u0111\u01b0\u1ee3c g\u1ecdi l\u00e0 “thu\u1ed1c s\u1ed1ng” (living drugs), \u0111\u00e1nh d\u1ea5u m\u1ed9t s\u1ef1 thay \u0111\u1ed5i m\u00f4 h\u00ecnh c\u01a1 b\u1ea3n trong d\u01b0\u1ee3c l\u00fd h\u1ecdc v\u00e0 \u0111i\u1ec1u tr\u1ecb ung th\u01b0.<\/p>\n\n\n\n

H\u1ec7 mi\u1ec5n d\u1ecbch c\u1ee7a con ng\u01b0\u1eddi, \u0111\u1eb7c bi\u1ec7t l\u00e0 c\u00e1c t\u1ebf b\u00e0o T, c\u00f3 kh\u1ea3 n\u0103ng t\u1ef1 nhi\u00ean trong vi\u1ec7c x\u00e1c \u0111\u1ecbnh v\u00e0 lo\u1ea1i b\u1ecf c\u00e1c t\u1ebf b\u00e0o b\u1ea5t th\u01b0\u1eddng, bao g\u1ed3m c\u1ea3 t\u1ebf b\u00e0o ung th\u01b0. Tuy nhi\u00ean, c\u00e1c kh\u1ed1i u \u00e1c t\u00ednh th\u01b0\u1eddng ph\u00e1t tri\u1ec3n c\u00e1c c\u01a1 ch\u1ebf ph\u1ee9c t\u1ea1p \u0111\u1ec3 tr\u1ed1n tr\u00e1nh s\u1ef1 gi\u00e1m s\u00e1t mi\u1ec5n d\u1ecbch n\u00e0y. Ch\u00fang c\u00f3 th\u1ec3 l\u00e0m gi\u1ea3m bi\u1ec3u hi\u1ec7n c\u00e1c kh\u00e1ng nguy\u00ean b\u1ec1 m\u1eb7t, t\u1ea1o ra m\u1ed9t m\u00f4i tr\u01b0\u1eddng vi m\u00f4 \u1ee9c ch\u1ebf mi\u1ec5n d\u1ecbch, ho\u1eb7c k\u00edch ho\u1ea1t c\u00e1c \u0111i\u1ec3m ki\u1ec3m so\u00e1t mi\u1ec5n d\u1ecbch \u0111\u1ec3 l\u00e0m b\u1ea5t ho\u1ea1t c\u00e1c t\u1ebf b\u00e0o T t\u1ea5n c\u00f4ng. Li\u1ec7u ph\u00e1p CAR-T \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf \u0111\u1ec3 v\u01b0\u1ee3t qua nh\u1eefng r\u00e0o c\u1ea3n n\u00e0y. B\u1eb1ng c\u00e1ch trang b\u1ecb cho t\u1ebf b\u00e0o T m\u1ed9t th\u1ee5 th\u1ec3 CAR, li\u1ec7u ph\u00e1p n\u00e0y cung c\u1ea5p m\u1ed9t c\u01a1 ch\u1ebf nh\u1eadn di\u1ec7n kh\u00e1ng nguy\u00ean m\u1edbi, m\u1ea1nh m\u1ebd v\u00e0 kh\u00f4ng ph\u1ee5 thu\u1ed9c v\u00e0o Ph\u1ee9c h\u1ee3p H\u00f2a h\u1ee3p M\u00f4 ch\u00ednh (Major Histocompatibility Complex – MHC). \u0110i\u1ec1u n\u00e0y cho ph\u00e9p c\u00e1c t\u1ebf b\u00e0o CAR-T “nh\u00ecn th\u1ea5y” v\u00e0 t\u1ea5n c\u00f4ng c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 ngay c\u1ea3 khi ch\u00fang \u0111\u00e3 m\u1ea5t kh\u1ea3 n\u0103ng tr\u00ecnh di\u1ec7n kh\u00e1ng nguy\u00ean th\u00f4ng th\u01b0\u1eddng, m\u1ed9t c\u01a1 ch\u1ebf tr\u1ed1n tho\u00e1t mi\u1ec5n d\u1ecbch ph\u1ed5 bi\u1ebfn. V\u1ec1 b\u1ea3n ch\u1ea5t, li\u1ec7u ph\u00e1p CAR-T “hu\u1ea5n luy\u1ec7n l\u1ea1i” h\u1ec7 mi\u1ec5n d\u1ecbch c\u1ee7a b\u1ec7nh nh\u00e2n \u0111\u1ec3 ch\u1ed1ng l\u1ea1i k\u1ebb th\u00f9 m\u00e0 tr\u01b0\u1edbc \u0111\u00e2y n\u00f3 kh\u00f4ng th\u1ec3 nh\u1eadn ra.<\/p>\n\n\n\n

S\u1ef1 ra \u0111\u1eddi c\u1ee7a li\u1ec7u ph\u00e1p CAR-T \u0111\u00e3 t\u1ea1o ra m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t trong \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh l\u00fd huy\u1ebft h\u1ecdc \u00e1c t\u00ednh, \u0111\u1eb7c bi\u1ec7t \u0111\u1ed1i v\u1edbi nh\u1eefng b\u1ec7nh nh\u00e2n b\u1ecb b\u1ec7nh t\u00e1i ph\u00e1t ho\u1eb7c kh\u00e1ng tr\u1ecb (R\/R) sau khi \u0111\u00e3 th\u1ea5t b\u1ea1i v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ti\u00eau chu\u1ea9n nh\u01b0 h\u00f3a tr\u1ecb li\u1ec7u, x\u1ea1 tr\u1ecb v\u00e0 gh\u00e9p t\u1ebf b\u00e0o g\u1ed1c t\u1ea1o m\u00e1u. Vi\u1ec7c C\u1ee5c Qu\u1ea3n l\u00fd Th\u1ef1c ph\u1ea9m v\u00e0 D\u01b0\u1ee3c ph\u1ea9m Hoa K\u1ef3 (FDA) ph\u00ea duy\u1ec7t c\u00e1c li\u1ec7u ph\u00e1p CAR-T \u0111\u1ea7u ti\u00ean v\u00e0o n\u0103m 2017 – Tisagenlecleucel (Kymriah)1<\/sup> cho b\u1ec7nh b\u1ea1ch c\u1ea7u c\u1ea5p d\u00f2ng lympho B (B-ALL) \u1edf tr\u1ebb em v\u00e0 thanh ni\u00ean, v\u00e0 Axicabtagene ciloleucel (Yescarta) cho u lympho t\u1ebf b\u00e0o B l\u1edbn lan t\u1ecfa (DLBCL) \u1edf ng\u01b0\u1eddi l\u1edbn – \u0111\u00e3 ch\u00ednh th\u1ee9c m\u1edf ra m\u1ed9t k\u1ef7 nguy\u00ean m\u1edbi trong y h\u1ecdc ch\u00ednh x\u00e1c v\u00e0 li\u1ec7u ph\u00e1p mi\u1ec5n d\u1ecbch t\u1ebf b\u00e0o. Nh\u1eefng th\u00e0nh c\u00f4ng ban \u0111\u1ea7u n\u00e0y kh\u00f4ng ch\u1ec9 mang l\u1ea1i hy v\u1ecdng cho nh\u1eefng b\u1ec7nh nh\u00e2n kh\u00f4ng c\u00f2n l\u1ef1a ch\u1ecdn \u0111i\u1ec1u tr\u1ecb m\u00e0 c\u00f2n x\u00fac t\u00e1c cho m\u1ed9t l\u00e0n s\u00f3ng nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n s\u00e2u r\u1ed9ng, m\u1edf r\u1ed9ng ti\u1ec1m n\u0103ng c\u1ee7a CAR-T sang c\u00e1c lo\u1ea1i ung th\u01b0 kh\u00e1c v\u00e0 th\u1eadm ch\u00ed c\u1ea3 c\u00e1c b\u1ec7nh kh\u00f4ng ph\u1ea3i ung th\u01b0.<\/p>\n\n\n\n

M\u1ed9t trong nh\u1eefng kh\u00eda c\u1ea1nh s\u00e2u s\u1eafc nh\u1ea5t c\u1ee7a c\u00f4ng ngh\u1ec7 CAR-T l\u00e0 n\u00f3 kh\u00f4ng ch\u1ec9 l\u00e0 m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ung th\u01b0 m\u00e0 c\u00f2n l\u00e0 m\u1ed9t n\u1ec1n t\u1ea3ng tr\u1ecb li\u1ec7u linh ho\u1ea1t. C\u01a1 ch\u1ebf c\u1ed1t l\u00f5i\u2014lo\u1ea1i b\u1ecf t\u1ebf b\u00e0o m\u1ed9t c\u00e1ch \u0111\u1eb7c hi\u1ec7u d\u1ef1a tr\u00ean kh\u00e1ng nguy\u00ean\u2014c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c \u00e1p d\u1ee5ng cho c\u00e1c b\u1ed1i c\u1ea3nh b\u1ec7nh l\u00fd kh\u00e1c nhau. V\u00ed d\u1ee5, trong \u0111i\u1ec1u tr\u1ecb ung th\u01b0 h\u1ea1ch, t\u00e1c d\u1ee5ng ph\u1ee5 “tr\u00fang m\u1ee5c ti\u00eau, ngo\u00e0i kh\u1ed1i u” (on-target, off-tumor) l\u00e0 t\u00ecnh tr\u1ea1ng b\u1ea5t s\u1ea3n t\u1ebf b\u00e0o B (B-cell aplasia) do CAR-T ti\u00eau di\u1ec7t c\u1ea3 t\u1ebf b\u00e0o B \u00e1c t\u00ednh v\u00e0 kh\u1ecfe m\u1ea1nh c\u00f3 bi\u1ec3u hi\u1ec7n CD19. T\u00ecnh tr\u1ea1ng n\u00e0y \u0111\u01b0\u1ee3c xem l\u00e0 m\u1ed9t \u0111\u1ed9c t\u00ednh c\u00f3 th\u1ec3 ki\u1ec3m so\u00e1t \u0111\u01b0\u1ee3c. Tuy nhi\u00ean, trong b\u1ed1i c\u1ea3nh c\u00e1c b\u1ec7nh t\u1ef1 mi\u1ec5n nh\u01b0 lupus ban \u0111\u1ecf h\u1ec7 th\u1ed1ng, ch\u00ednh vi\u1ec7c lo\u1ea1i b\u1ecf c\u00e1c t\u1ebf b\u00e0o B t\u1ef1 ph\u1ea3n \u1ee9ng n\u00e0y l\u1ea1i l\u00e0 m\u1ee5c ti\u00eau \u0111i\u1ec1u tr\u1ecb mong mu\u1ed1n.2<\/sup> S\u1ef1 \u0111\u1ed1i ng\u1eabu n\u00e0y cho th\u1ea5y ti\u1ec1m n\u0103ng c\u1ee7a CAR-T l\u00e0 m\u1ed9t c\u00f4ng ngh\u1ec7 n\u1ec1n t\u1ea3ng c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c \u0111i\u1ec1u ch\u1ec9nh \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb m\u1ed9t lo\u1ea1t c\u00e1c b\u1ec7nh l\u00fd qua trung gian t\u1ebf b\u00e0o, v\u01b0\u1ee3t xa kh\u1ecfi ph\u1ea1m vi ung th\u01b0 h\u1ecdc ban \u0111\u1ea7u.<\/p>\n\n\n\n

D\u01b0\u1edbi \u0111\u00e2y l\u00e0 c\u00e1c th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng li\u00ean quan \u0111\u1ebfn li\u1ec7u ph\u00e1p CAR-T<\/p>\n\n\n\n

B\u1ea3ng 3: T\u00f3m t\u1eaft c\u00e1c Li\u1ec7u ph\u00e1p CAR-T \u0111\u01b0\u1ee3c Ph\u00ea duy\u1ec7t v\u00e0 c\u00e1c Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng (D\u1eef li\u1ec7u 2020-2025)<\/strong><\/p>\n\n\n\n

T\u00ean th\u01b0\u01a1ng m\u1ea1i (Ho\u1ea1t ch\u1ea5t)<\/td>M\u1ee5c ti\u00eau\/Mi\u1ec1n \u0111\u1ed3ng k\u00edch th\u00edch<\/td>Ch\u1ec9 \u0111\u1ecbnh ch\u00ednh<\/td>Th\u1eed nghi\u1ec7m Then ch\u1ed1t<\/td>ORR (%)<\/td>CR (%)<\/td>mOS (th\u00e1ng)<\/td>mPFS (th\u00e1ng)<\/td><\/tr>
Kymriah<\/strong> (tisa-cel)1<\/sup><\/td>CD19 \/ 4-1BB<\/td>B-ALL (tr\u1ebb em\/thanh ni\u00ean)<\/td>ELIANA<\/td>82<\/td>60<\/td>55% t\u1ea1i 5 n\u0103m<\/td>43.8<\/td><\/tr>
<\/td><\/td>DLBCL R\/R<\/td>JULIET<\/td>53<\/td>39<\/td>11.1<\/td>2.9<\/td><\/tr>
Yescarta<\/strong> (axi-cel)3<\/sup><\/td>CD19 \/ CD28<\/td>LBCL R\/R (\u22652 d\u00f2ng)<\/td>ZUMA-1, ZUMA-7<\/td>74-83<\/td>54-65<\/td>25.8 (ZUMA-1)<\/td>5.9 (ZUMA-1)<\/td><\/tr>
<\/td><\/td>iNHL R\/R<\/td>ZUMA-5<\/td>94 (FL)<\/td>80 (FL)<\/td>Ch\u01b0a \u0111\u1ea1t<\/td>40.2 (FL)<\/td><\/tr>
Tecartus<\/strong> (brexu-cel)4<\/sup><\/td>CD19 \/ CD28<\/td>MCL R\/R<\/td>ZUMA-2<\/td>91<\/td>68<\/td>46.6<\/td>28.2 (DOR)<\/td><\/tr>
<\/td><\/td>B-ALL R\/R (ng\u01b0\u1eddi l\u1edbn)<\/td>ZUMA-3<\/td>71 (CR\/CRi)<\/td>56<\/td>26.0<\/td>11.6 (RFS)<\/td><\/tr>
Breyanzi<\/strong> (liso-cel)5<\/sup><\/td>CD19 \/ 4-1BB<\/td>LBCL R\/R (\u22652 d\u00f2ng)<\/td>TRANSFORM<\/td>86<\/td>68<\/td>Ch\u01b0a \u0111\u1ea1t<\/td>10.1<\/td><\/tr>
<\/td><\/td>FL\/MZL R\/R<\/td>TRANSCEND FL<\/td>95.5 (MZL)<\/td>62.1 (MZL)<\/td>90.4% t\u1ea1i 2 n\u0103m<\/td>85.7% t\u1ea1i 2 n\u0103m<\/td><\/tr>
Abecma<\/strong> (ide-cel)6<\/sup><\/td>BCMA \/ 4-1BB<\/td>MM R\/R (\u22652 d\u00f2ng)<\/td>KarMMa, KarMMa-3<\/td>73 (KarMMa)<\/td>33 (KarMMa)<\/td>19.4 (KarMMa)<\/td>8.8 (KarMMa)<\/td><\/tr>
Carvykti<\/strong> (cilta-cel)7<\/sup><\/td>BCMA \/ 4-1BB<\/td>MM R\/R (\u22651 d\u00f2ng)<\/td>CARTITUDE-1, 4<\/td>98 (C-1)<\/td>83 (C-1)<\/td>60.7 (C-1)<\/td>34.9 (C-1)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

L\u01b0u \u00fd: D\u1eef li\u1ec7u \u0111\u01b0\u1ee3c t\u1ed5ng h\u1ee3p t\u1eeb c\u00e1c b\u00e1o c\u00e1o theo d\u00f5i d\u00e0i h\u1ea1n kh\u00e1c nhau v\u00e0 c\u00f3 th\u1ec3 thay \u0111\u1ed5i t\u00f9y thu\u1ed9c v\u00e0o th\u1eddi \u0111i\u1ec3m c\u1eaft d\u1eef li\u1ec7u v\u00e0 qu\u1ea7n th\u1ec3 b\u1ec7nh nh\u00e2n c\u1ee5 th\u1ec3. ORR: T\u1ef7 l\u1ec7 \u0111\u00e1p \u1ee9ng to\u00e0n b\u1ed9; CR: T\u1ef7 l\u1ec7 \u0111\u00e1p \u1ee9ng ho\u00e0n to\u00e0n; mOS: Th\u1eddi gian s\u1ed1ng c\u00f2n to\u00e0n b\u1ed9 trung v\u1ecb; mPFS: Th\u1eddi gian s\u1ed1ng c\u00f2n kh\u00f4ng ti\u1ebfn tri\u1ec3n trung v\u1ecb; DOR: Th\u1eddi gian \u0111\u00e1p \u1ee9ng; RFS: Th\u1eddi gian s\u1ed1ng c\u00f2n kh\u00f4ng t\u00e1i ph\u00e1t.<\/em>
<\/p>\n\n\n\n

M\u1eb7c d\u00f9 c\u00f3 c\u00e1c k\u1ebft qu\u1ea3 t\u00edch c\u1ef1c, nh\u01b0ng li\u1ec7u ph\u00e1p CAR-T v\u1eabn c\u00f2n m\u1ed9t s\u1ed1 r\u00e0o c\u1ea3n:<\/p>\n\n\n\n

    \n
  • L\u1ef1a ch\u1ecdn Kh\u00e1ng nguy\u00ean v\u00e0 T\u00ednh kh\u00f4ng \u0110\u1ed3ng nh\u1ea5t:<\/strong> Vi\u1ec7c t\u00ecm ki\u1ebfm c\u00e1c kh\u00e1ng nguy\u00ean \u0111\u1eb7c hi\u1ec7u cho kh\u1ed1i u v\u00e0 \u0111\u01b0\u1ee3c bi\u1ec3u hi\u1ec7n \u0111\u1ed3ng nh\u1ea5t tr\u00ean t\u1ea5t c\u1ea3 c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 l\u00e0 c\u1ef1c k\u1ef3 kh\u00f3 kh\u0103n. Nhi\u1ec1u kh\u00e1ng nguy\u00ean ti\u1ec1m n\u0103ng l\u00e0 c\u00e1c kh\u00e1ng nguy\u00ean li\u00ean quan \u0111\u1ebfn kh\u1ed1i u (Tumor-Associated Antigens – TAA), c\u0169ng \u0111\u01b0\u1ee3c bi\u1ec3u hi\u1ec7n \u1edf m\u1ee9c \u0111\u1ed9 th\u1ea5p tr\u00ean c\u00e1c m\u00f4 kh\u1ecfe m\u1ea1nh, l\u00e0m t\u0103ng nguy c\u01a1 \u0111\u1ed9c t\u00ednh “tr\u00fang m\u1ee5c ti\u00eau, ngo\u00e0i kh\u1ed1i u” nghi\u00eam tr\u1ecdng. Ngo\u00e0i ra, c\u00e1c kh\u1ed1i u \u0111\u1eb7c th\u01b0\u1eddng l\u00e0 m\u1ed9t t\u1eadp h\u1ee3p kh\u00f4ng \u0111\u1ed3ng nh\u1ea5t c\u1ee7a c\u00e1c d\u00f2ng t\u1ebf b\u00e0o, m\u1ed9t s\u1ed1 c\u00f3 th\u1ec3 kh\u00f4ng bi\u1ec3u hi\u1ec7n kh\u00e1ng nguy\u00ean m\u1ee5c ti\u00eau, t\u1ea1o \u0111i\u1ec1u ki\u1ec7n cho s\u1ef1 tr\u1ed1n tho\u00e1t mi\u1ec5n d\u1ecbch.<\/li>\n\n\n\n
  • S\u1ef1 Di chuy\u1ec3n v\u00e0 X\u00e2m nh\u1eadp c\u1ee7a CAR-T:<\/strong> Kh\u00f4ng gi\u1ed1ng nh\u01b0 c\u00e1c t\u1ebf b\u00e0o ung th\u01b0 m\u00e1u d\u1ec5 ti\u1ebfp c\u1eadn trong tu\u1ea7n ho\u00e0n, c\u00e1c kh\u1ed1i u \u0111\u1eb7c \u0111\u01b0\u1ee3c b\u1ea3o v\u1ec7 b\u1edfi c\u00e1c r\u00e0o c\u1ea3n v\u1eadt l\u00fd. C\u00e1c t\u1ebf b\u00e0o CAR-T ph\u1ea3i tho\u00e1t ra kh\u1ecfi m\u1ea1ch m\u00e1u, di chuy\u1ec3n qua m\u1ed9t l\u1edbp m\u00f4 \u0111\u1ec7m d\u00e0y \u0111\u1eb7c (stroma) v\u00e0 m\u1ed9t m\u1ea1ng l\u01b0\u1edbi m\u1ea1ch m\u00e1u b\u1ea5t th\u01b0\u1eddng \u0111\u1ec3 \u0111\u1ebfn \u0111\u01b0\u1ee3c l\u00f5i kh\u1ed1i u.<\/li>\n\n\n\n
  • M\u00f4i tr\u01b0\u1eddng Vi m\u00f4 Kh\u1ed1i u \u1ee8c ch\u1ebf Mi\u1ec5n d\u1ecbch (TME):<\/strong> TME c\u1ee7a c\u00e1c kh\u1ed1i u \u0111\u1eb7c l\u00e0 m\u1ed9t m\u00f4i tr\u01b0\u1eddng kh\u1eafc nghi\u1ec7t, thi\u1ebfu oxy, ngh\u00e8o dinh d\u01b0\u1ee1ng v\u00e0 ch\u1ee9a \u0111\u1ea7y c\u00e1c t\u1ebf b\u00e0o \u1ee9c ch\u1ebf mi\u1ec5n d\u1ecbch (nh\u01b0 t\u1ebf b\u00e0o T \u0111i\u1ec1u h\u00f2a – Tregs, t\u1ebf b\u00e0o \u1ee9c ch\u1ebf ngu\u1ed3n g\u1ed1c t\u1ee7y – MDSCs) v\u00e0 c\u00e1c ph\u00e2n t\u1eed \u1ee9c ch\u1ebf (nh\u01b0 PD-L1, TGF-\u03b2). M\u00f4i tr\u01b0\u1eddng n\u00e0y l\u00e0m cho c\u00e1c t\u1ebf b\u00e0o CAR-T nhanh ch\u00f3ng b\u1ecb m\u1ea5t ch\u1ee9c n\u0103ng.<\/li>\n<\/ul>\n\n\n\n

    M\u1eb7c d\u00f9 v\u1eady, t\u01b0\u01a1ng lai c\u1ee7a li\u1ec7u ph\u00e1p CAR-T r\u1ea5t t\u01b0\u01a1i s\u00e1ng v\u00e0 \u0111\u1ea7y h\u1ee9a h\u1eb9n. L\u0129nh v\u1ef1c n\u00e0y \u0111ang ph\u00e1t tri\u1ec3n v\u1edbi t\u1ed1c \u0111\u1ed9 nhanh ch\u00f3ng, \u0111\u01b0\u1ee3c th\u00fac \u0111\u1ea9y b\u1edfi s\u1ef1 h\u1ed9i t\u1ee5 c\u1ee7a c\u00e1c c\u00f4ng ngh\u1ec7 ti\u00ean ti\u1ebfn. Vi\u1ec7c t\u00edch h\u1ee3p k\u1ef9 thu\u1eadt di truy\u1ec1n ch\u00ednh x\u00e1c nh\u01b0 CRISPR\/Cas9, c\u00e1c h\u1ec7 th\u1ed1ng ph\u00e2n ph\u1ed1i m\u1edbi nh\u01b0 h\u1ea1t nano lipid, v\u00e0 c\u00e1c m\u00f4 h\u00ecnh s\u1ea3n xu\u1ea5t s\u00e1ng t\u1ea1o nh\u01b0 li\u1ec7u ph\u00e1p d\u1ecb th\u00e2n “s\u1eb5n c\u00f3” v\u00e0 s\u1ea3n xu\u1ea5t ph\u00e2n c\u1ea5p, h\u1ee9a h\u1eb9n s\u1ebd kh\u1eafc ph\u1ee5c nhi\u1ec1u h\u1ea1n ch\u1ebf hi\u1ec7n t\u1ea1i. Vi\u1ec7c m\u1edf r\u1ed9ng \u1ee9ng d\u1ee5ng sang c\u00e1c kh\u1ed1i u \u0111\u1eb7c v\u00e0 c\u00e1c b\u1ec7nh kh\u00f4ng \u00e1c t\u00ednh nh\u01b0 b\u1ec7nh t\u1ef1 mi\u1ec5n cho th\u1ea5y s\u1ef1 ti\u1ebfn h\u00f3a c\u1ee7a CAR-T t\u1eeb m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ung th\u01b0 chuy\u00ean bi\u1ec7t th\u00e0nh m\u1ed9t n\u1ec1n t\u1ea3ng tr\u1ecb li\u1ec7u r\u1ed9ng l\u1edbn. Khi c\u00f4ng ngh\u1ec7 ti\u1ebfp t\u1ee5c tr\u01b0\u1edfng th\u00e0nh, li\u1ec7u ph\u00e1p CAR-T c\u00f3 ti\u1ec1m n\u0103ng tr\u1edf n\u00ean an to\u00e0n h\u01a1n, hi\u1ec7u qu\u1ea3 h\u01a1n v\u00e0 d\u1ec5 ti\u1ebfp c\u1eadn h\u01a1n, ti\u1ebfp t\u1ee5c \u0111\u1ecbnh ngh\u0129a l\u1ea1i c\u00e1c gi\u1edbi h\u1ea1n c\u1ee7a y h\u1ecdc v\u00e0 thay \u0111\u1ed5i cu\u1ed9c s\u1ed1ng c\u1ee7a b\u1ec7nh nh\u00e2n tr\u00ean to\u00e0n th\u1ebf gi\u1edbi.<\/p>\n\n\n\n

    ——-
    <\/p>\n\n\n\n

    T\u00e0i li\u1ec7u tham kh\u1ea3o<\/p>\n\n\n\n

      \n
    1. Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc). 2017 Nov;53(11):597-608. doi: 10.1358\/dot.2017.53.11.2725754. PMID: 29451276.<\/li>\n\n\n\n
    2. Wu Y, Han L, Wang Y, Gu M, Wang Y, Gao J, Huang H, Li C. CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases. Front Immunol. 2025 Aug 13;16:1625166. doi: 10.3389\/fimmu.2025.1625166. PMID: 40881712; PMCID: PMC12380546.<\/li>\n\n\n\n
    3. Chartier M, Filosto S, Peyret T, Chiney M, Milletti F, Budka J, Ndi A, Dong J, Vardhanabhuti S, Mao D, Duffull S, Dodds M, Shen R. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma. Clin Pharmacokinet. 2024 Sep;63(9):1283-1299. doi: 10.1007\/s40262-024-01413-z. Epub 2024 Sep 6. PMID: 39240498.<\/li>\n\n\n\n
    4. Brexucabtagene Autoleucel (Tecartus): CADTH Reimbursement Review: Therapeutic area: Acute lymphoblastic leukemia [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jun. Clinical Review.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK595344\/<\/li>\n\n\n\n
    5. Lisocabtagene Maraleucel (Breyanzi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603593\/<\/li>\n\n\n\n
    6. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200\/JCO.22.01365. Epub 2023 Jan 9. PMID: 36623248; PMCID: PMC10082273.<\/li>\n\n\n\n
    7. Ciltacabtagene Autoleucel (Carvykti): Indication: For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide: Reimbursement Recommendation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK610233\/


      <\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Li\u1ec7u ph\u00e1p t\u1ebf b\u00e0o th\u1ee5 th\u1ec3 kh\u00e1ng nguy\u00ean kh\u1ea3m tr\u00ean t\u1ebf b\u00e0o T (Chimeric Antigen Receptor T-cell – CAR-T) l\u00e0 m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb mi\u1ec5n d\u1ecbch mang t\u00ednh c\u00e1ch m\u1ea1ng, thu\u1ed9c nh\u00f3m li\u1ec7u ph\u00e1p chuy\u1ec3n t\u1ebf b\u00e0o nu\u00f4i, trong \u0111\u00f3 c\u00e1c t\u1ebf b\u00e0o lympho T c\u1ee7a ch\u00ednh b\u1ec7nh nh\u00e2n \u0111\u01b0\u1ee3c bi\u1ebfn \u0111\u1ed5i di truy\u1ec1n […]<\/p>\n","protected":false},"author":27,"featured_media":2125,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[31],"tags":[],"class_list":["post-2123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tin-tuc"],"jetpack_featured_media_url":"https:\/\/biomedmart.com.vn\/etc\/wp-content\/uploads\/2025\/09\/1-1.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/posts\/2123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/comments?post=2123"}],"version-history":[{"count":1,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/posts\/2123\/revisions"}],"predecessor-version":[{"id":2126,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/posts\/2123\/revisions\/2126"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/media\/2125"}],"wp:attachment":[{"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/media?parent=2123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/categories?post=2123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedmart.com.vn\/etc\/wp-json\/wp\/v2\/tags?post=2123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}